Stay updated on Daratumumab in High-Risk MGUS & Low-Risk Smoldering Clinical Trial

Sign up to get notified when there's something new on the Daratumumab in High-Risk MGUS & Low-Risk Smoldering Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Daratumumab in High-Risk MGUS & Low-Risk Smoldering Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:51:47.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a potential update or revision in the data related to a Phase II study of the CD38 Antibody Daratumumab in patients with high-risk MGUS and low-risk smoldering multiple myeloma, focusing on testing the effectiveness of the investigational drug.
    Difference
    0.1%
    Check dated 2024-06-06T14:39:22.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to provide a more detailed explanation of eligibility criteria, including examples such as a person's general health condition or prior treatments. The new description emphasizes the importance of these criteria in selecting participants for the study.
    Difference
    46%
    Check dated 2024-05-22T21:38:01.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.9%
    Check dated 2024-04-30T22:44:12.000Z thumbnail image

Stay in the know with updates to Daratumumab in High-Risk MGUS & Low-Risk Smoldering Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Daratumumab in High-Risk MGUS & Low-Risk Smoldering Clinical Trial page.